P. Morentin Gutierrez

Design and optimization of pyrazinecarboxamide-based inhibitors of diacylglycerol acyltransferase 1 (DGAT1) leading to a clinical candidate dimethylpyrazinecarboxamide phenylcyclohexylacetic acid (AZD7687).

Magnus J. Johansson, Tobias Noeske, Robert D. M. Davies, 2012, Journal of medicinal chemistry.

Evolving data analysis of an Oral Lipid Tolerance Test toward the standard for the Oral Glucose Tolerance Test: Cross species modeling effects of AZD7687 on plasma triacylglycerol

J. Yates, C. Nilsson, S. Birtles, 2019, Pharmacology research & perspectives.

Continuous inhibition of 11β‐hydroxysteroid dehydrogenase type I in adipose tissue leads to tachyphylaxis in humans and rats but not in mice

J. Swales, Jenny Casey Eriksson, B. Leighton, 2015, British journal of pharmacology.

Intermittent High-Dose Scheduling of AZD8835, a Novel Selective Inhibitor of PI3Kα and PI3Kδ, Demonstrates Treatment Strategies for PIK3CA-Dependent Breast Cancers

O. Delpuech, S. Green, Á. Avivar-Valderas, 2016, Molecular Cancer Therapeutics.

Discovery of Clinical Candidate AZD0095, a Selective Inhibitor of Monocarboxylate Transporter 4 (MCT4) for Oncology.

G. Lamont, D. Buttar, S. Critchlow, 2022, Journal of medicinal chemistry.

An integrated modelling approach for targeted degradation: insights on optimization, data requirements and PKPD predictions from semi- or fully-mechanistic models and exact steady state solutions

S. Guzzetti, P. Morentin Gutierrez, 2023, Journal of Pharmacokinetics and Pharmacodynamics.

NIMBLE: A Phase I/II Study of AZD0466 Monotherapy or in Combination in Patients with Advanced Hematological Malignancies

M. Konopleva, G. Fabbri, B. Davies, 2021, Blood.

Design and optimization of pyrazinecarboxamide-based inhibitors of diacylglycerol acyltransferase 1 (DGAT1) leading to a clinical candidate dimethylpyrazinecarboxamide phenylcyclohexylacetic acid (AZD7687).

Magnus J. Johansson, Tobias Noeske, Robert D. M. Davies, 2012, Journal of medicinal chemistry.